北京大学学报(医学版) ›› 2018, Vol. 50 ›› Issue (6): 1117-1119. doi: 10.19723/j.issn.1671-167X.2018.06.032

• 病例报告 • 上一篇    下一篇

原发性骨髓纤维化引起的继发性痛风1例

季兰岚,郝燕捷,张卓莉()   

  1. 北京大学第一医院风湿免疫科,北京 100034
  • 收稿日期:2018-07-09 出版日期:2018-12-18 发布日期:2018-12-18
  • 通讯作者: 张卓莉 E-mail:zhuoli.zhang@126.com

A case of gout secondary to primary myelofibrosis

Lan-lan JI,Yan-jie HAO,Zhuo-li ZHANG()   

  1. Department of Rheumatology and Immunology,Peking University First Hospital, Beijing 100034, China
  • Received:2018-07-09 Online:2018-12-18 Published:2018-12-18
  • Contact: Zhuo-li ZHANG E-mail:zhuoli.zhang@126.com

RICH HTML

  

摘要:

关键词: 继发性痛风, 痛风石, 原发性骨髓纤维化, 骨髓增殖性疾病

Abstract:

A 52-year-old man was referred to our department with a 2-year history of polyarthritis. He was diagnosed as gout due to acute arthritis of bilateral feet dorsum 2 years ago,but he didn’t receive any standard treatment. 1 year ago,there were more and more joints evolved during the gout attack,and many subcutaneous nodules occurred. When he presented to our clinic 1 month ago,the urate acid level was as high as 715 μmol/L. Moreover,we could find bone erosion in the X rays of his hand and foot,as well as synovitis,double contour sign and tophus on the ultrasound examination. The diagnosis of gout was clearly and definitely. However,he had leukocytosis and thrombocytosis for 4 years in the past history,and the urate acid level was only 400 μmol/L at that time. He also had well-controlled hypertension. The family history was unremarkable. Furthermore,we found megalosplenia on his physical examination. The bone marrow examination showed myelofibrosis and JAK2 V617F gene was positive. He was diagnosed as primary myelofibrosis and treated with interferon-α,together with urate acid-lowing therapy (febuxostat 60 mg once daily). Following-up for 1 year,the dosage of febuxostat decreased to 40 mg once daily,and the patient didn’t have gout attack again,some of the tophus diminished,and the urate acid level ranged from 400 to 500 μmol/L. Gout is a common disease in clinical practice,usually combined with metabolic syndrome,chronic renal failure and specific drugs using (diuretic and calcineurin inhibitors). However,it is relatively rare to see gout associated with myeloproliferative diseases,including polycythemia vera,primary thrombocythemia,primary myelofibrosis and chronic myelocytic leukemia.In these diseases,the turnover of nucleic acids is greatly augmented,and an excess of purine metabolites,including uric acid,is released. In the natural course of gout,the appearance of tophus from the first onset of arthritis usually takes several years. This patient only had one traditional risk factor,but his urate acid level was remarkably high and he developed tophus in a short term. After treatment of primary myelofibrosis,the symptom of gout partially alleviated. Careful physical examination and medical history taking lead to the diagnosis of secondary gout,which should be reminded in the daily practice.

Key words: Secondary gout, Tophus, Primary myelofibrosis, Myeloproliferative diseases

中图分类号: 

  • R593

图1

双手腕(A)及双足(B)X线片,箭头所指可见骨质破坏"

图2

左足距骨双轨征,左足距骨横断面扫查可见距骨上方双轨征形成(箭头)"

图3

右足痛风石,右足距舟关节上方可见一低-高混杂回声团块影,边界清晰,内可见点状多普勒血流信号(箭头)"

[1] 中华医学会风湿病学分会. 2016中国痛风诊疗指南[J]. 中华内科杂志, 2016,55(11):892-899.
[2] Neogi T, Jansen TLTA, Dalbeth N , et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Ann Rheum Dis, 2015,74(10):1789-1798.
doi: 10.1136/annrheumdis-2015-208237 pmid: 4602275
[3] Yü TF . Secondary gout associated with myeloproliferative diseases[J]. Arthritis Rheum, 1965,8(5):765-771.
doi: 10.1002/art.1780080439 pmid: 5216775
[4] Gutman AB . The past four decades of progress in the knowledge of gout, with an assessment of the present status[J]. Arthritis Rheum, 1973,16(4):431-445.
doi: 10.1002/(ISSN)1529-0131
[5] Takahashi H, Hattori A, Shibata A . Profile of blood coagulation and fibrinolysis in chronic myeloproliferative disorders[J]. Tohoku J Exp Med, 1982,138(1):71-80.
doi: 10.1620/tjem.138.71 pmid: 6959382
[6] Barbui T, Carobbio A, Cervantes F , et al. Thrombosis in primary myelofibrosis: incidence and risk factors[J]. Blood, 2010,115(4):778-782.
doi: 10.1182/blood-2009-08-238956 pmid: 19965680
[7] Liu TT, Chen JB, Chen WJ , et al. Idiopathic myelofibrosis associated with renal extramedullary hematopoiesis and nephrotic syndrome: case report[J]. Chang Gung Med J, 2000,23(3):169-174.
pmid: 15641221
[1] 魏慧, 张警丰, 姚中强, 赵金霞. 类风湿关节炎合并慢性病贫血患者的临床特征及相关因素[J]. 北京大学学报(医学版), 2026, 58(2): 307-312.
[2] 初吉燕, 李萍, 田竞, 付笛语, 郭琳, 孙蕊, 李亚娣. 黑色素瘤缺乏因子2介导的细胞焦亡通路在特发性炎性肌病患者外周血单个核细胞中的表达[J]. 北京大学学报(医学版), 2026, 58(1): 175-183.
[3] 刘源, 石桂秀. 干燥综合征到干燥病的命名变迁[J]. 北京大学学报(医学版), 2025, 57(6): 1015-1017.
[4] 练益瑞, 刘静璇, 赵亮, 赵静, 臧思田, 李玉慧. 抗PM/Scl抗体相关风湿性疾病谱及其在特发性炎性肌病中的免疫学特征[J]. 北京大学学报(医学版), 2025, 57(6): 1018-1023.
[5] 吴滔, 林建子, 朱亚锋, 马剑达, 贾霈雯, 杨莉娟, 潘婕, 邹耀威, 杨迎, 卢烨, 戴冽. 血清蛋白质谱筛选及验证类风湿关节炎患者肌肉量减少的生物标志物[J]. 北京大学学报(医学版), 2025, 57(6): 1024-1031.
[6] 林文灏, 谢阳, 王芳晴, 王淑盈, 刘香君, 胡凡磊, 贾园. 基于B细胞单细胞转录组测序的干燥综合征分子分型[J]. 北京大学学报(医学版), 2025, 57(6): 1032-1041.
[7] 向钊, 杨莉, 杨静. 非靶向代谢组学揭示原发性干燥综合征血小板减少患者血清差异代谢物及代谢通路[J]. 北京大学学报(医学版), 2025, 57(6): 1042-1050.
[8] 赵亚云, 倪梦凡, 李雪, 王蓓, 程功, 何菁, 金月波. 利妥昔单抗治疗原发性干燥综合征肾损害的临床疗效和安全性[J]. 北京大学学报(医学版), 2025, 57(6): 1051-1060.
[9] 彭嘉婧, 崔莉. 以眼部病变首发的结节病的临床特征及预后[J]. 北京大学学报(医学版), 2025, 57(6): 1061-1066.
[10] 高雅静, 李正芳, 马梦思, 武丽君. SII和SIRI对白塞病葡萄膜炎的风险预测及疾病活动度和预后的评估[J]. 北京大学学报(医学版), 2025, 57(6): 1067-1073.
[11] 王晓林, 郭邵逸, 陈大召, 温锡杰, 华勇, 张亮, 张秦. 全髋关节置换术治疗系统性红斑狼疮继发股骨头缺血性坏死的随访研究[J]. 北京大学学报(医学版), 2025, 57(6): 1081-1088.
[12] 吴昕峰, 满斯亮, 陈大召, 华勇, 温锡杰, 丁盈月, 张亮, 侯秀娟. 中轴型脊柱关节炎合并髋关节终末期受累的长期影像学参数:单中心24年大样本回顾研究[J]. 北京大学学报(医学版), 2025, 57(6): 1089-1095.
[13] 兰静雯, 陈哲, 程永静, 赵丽珂. 老年结缔组织病相关间质性肺病临床特征及抗纤维化治疗的疗效和安全性[J]. 北京大学学报(医学版), 2025, 57(6): 1101-1106.
[14] 李岩岩, 刘香君, 李公明, 李春, 贾园. 抗磷脂综合征患者就医行为及治疗现状调查[J]. 北京大学学报(医学版), 2025, 57(6): 1107-1112.
[15] 卫春, 杨月, 赵新菊, 刘栩, 贾园. 系统性红斑狼疮合并自身免疫性郎飞结病1例[J]. 北京大学学报(医学版), 2025, 57(6): 1174-1179.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!